Investing.com - Financial Markets Worldwide
Get 40% Off
Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Key events next week - healthcare

Published 04/13/2018, 09:56 AM
Updated 04/13/2018, 09:56 AM
© Reuters. Key events next week - healthcare
  • Noteworthy events during the week of April 15 - 21 for healthcare investors.
  • Monday (4/16): FDA action date for Bristol-Myers Squibb's (NYSE:BMY) Opdivo/Yervoy combo in intermediate/poor-risk renal cell carcinoma.
  • Bristol-Myers Squibb investor event: review of data presented at the American Association for Cancer Research (AACR) Annual Meeting.
  • Universal Influenza Vaccines Conference, Lausanne, Switzerland. BiondVax Pharmaceuticals (NASDAQ:BVXV): Mid-stage M-001 data.
  • Tuesday (4/17): FDA action date for Rigel Pharmaceuticals ' (NASDAQ:RIGL) Tavalisse (fostamatinib) for chronic/persistent immune thrombocytopenia.
  • FDA action date for Ultragenyx Pharmaceutical's (NASDAQ:RARE) Crysvita (burosumab) for X-linked hypophosphatemia.
  • Q1 earnings (premarket): UnitedHealth Group (NYSE:UNH), Johnson & Johnson (NYSE:JNJ).
  • Wednesday (4/18): Abbott (NYSE:ABT) Q1 results (premarket).
  • Thursday (4/19): FDA advisory committee review of GW Pharmaceuticals' (NASDAQ:GWPH) cannabidiol oral solution for Lennox-Gastaut or Dravet syndrome.
  • Revance Therapeutics (NASDAQ:RVNC): Investor Day, NYC.
  • Saturday (4/21): European Congress of Clinical Microbiology and Infectious Diseases ((ECCMID)), Madrid (4 days). Motif bio (NASDAQ:MTFB): Three iclaprim abstracts including P3 data vs. vancomycin in ABSSSI from Gram-positive bacteria. Cidara Therapeutics (NASDAQ:CDTX): Preclinical data on rezafungin. Achaogen (NASDAQ:AKAO): Plazomicin data. SCYNEXIS (NASDAQ:SCYX): SCY-078 data. Tetraphase Pharmaceuticals (NASDAQ:TTPH): P3 eravacycline data. Cardiome Pharma (NASDAQ:CRME): Data on Xydalba and Zevtera/Mabelio. Paratek Pharmaceuticals (NASDAQ:PRTK): P3 omadacycline data in ABSSSI. Nabriva Therapeutics (NASDAQ:NBRV): Lefamulin data.
  • American Academy of Neurology Annual Meeting, Los Angeles (7 days). MediciNova (NASDAQ:MNOV): P1b/2a data on MN-166 in ALS. BrainStorm Cell Therapeutics (NASDAQ:BCLI): P2 NurOwn micro-RNA biomarker data and ALSFR-R subgroup analyses. Ovid Therapeutics (NASDAQ:OVID): OV101 data, TAK-035/OV935 data. Intec Pharma (NASDAQ:NTEC): P2 safety and PK data on Accordion Pill. GW Pharmaceuticals (GWPH): P3 Epidiolex data in Lennox-Gastaut and Dravet. Adamas Pharmaceuticals (NASDAQ:ADMS): GOCOVRI (amantadine) data.
  • Now read: Aclaris Therapeutics partners with Cipher Pharmaceuticals to commercialize A-101 40% for the treatment of raised seborrheic keratoses in Canada
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .


Original article

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.